Gilead Sciences and Kite Pharma’s Yescarta (axicabtagene ciloleucel), the first chimeric antigen receptor (CAR) T-cell therapy approved by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with follicular lymphoma (FL). Follicular lymphoma is the second most common form of indolent non-Hodgkin lymphoma (iNHL), with the tumors typically growing more slowly as well as much more aggressively. “As we look to bring the hope of survival to more patients in need, today’s FDA decision represents a real step forward in our commitment in hematologic malignancies. Advancing CAR T therapies for patients across lymphomas remains a cornerstone of our cell therapy development program, and we are excited about the potential of Yescarta for patients with indolent follicular lymphoma,” stated Christi Shaw, CEO of Kite.

Read more here.